Clinical Characteristics and Prognosis of Elderly Patients with Medium and High risk Myelodysplastic Syndrome.
10.19746/j.cnki.issn.1009-2137.2021.03.029
- Author:
Wen-Shu ZHAO
1
;
Zhi-Ping FAN
1
;
Fen HUANG
1
;
Na XU
1
;
Qian-Li JIANG
1
;
Qi-Fa LIU
1
;
Min DAI
2
Author Information
1. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.
2. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China,E-mail: berrydai2003@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Aged;
Chromosome Aberrations;
Hematopoietic Stem Cell Transplantation;
Humans;
Myelodysplastic Syndromes;
Prognosis;
Retrospective Studies
- From:
Journal of Experimental Hematology
2021;29(3):840-846
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical characteristics and prognosis of patients with medium and high risk myelodysplastic syndrome (MDS).
METHODS:97 MDS patients above the age of 60 treated in Nanfang Hospital, Southern Medical University from February 2011 to August 2020 were enrolled. The clinical characteristics and prognosis of the MDS patients with medium risk, high risk or very high risk based on IPSS-R category were retrospectively analyzed. According to the difference of treatment regimes, the patients were divided into the transplantation group, chemotherapy group and other treatment group, and the efficacy among the patients in the 3 groups were analyzed.
RESULTS:MDS with excess blast (MDS-EB) in the elderly patients with medium and high risk MDS were the most common, 47.4% of the patients with abnormal chromosome karyotypes, and 23.7% with complex karyotypes (≥3). 97.3% of the patients showed at least one gene mutation, and TP53 mutations were detected in nearly 20% of the patients with medium and high risk. Multivariate analysis showed that IPSS-R category and treatment regimes were the factors affecting the prognosis of elderly patients with medium and high risk MDS. The median overall survival (OS) time of the patients in the 3 groups showed significant difference (P=0.012), and the median OS of the patients in the transplantation group was significantly longer than that in the chemotherapy group and other group (P=0.003,P=0.014,respectively), while there was no significant difference in median OS between chemotherapy group and other treatment group (P=0.685).
CONCLUSION:Elderly MDS patients with medium and high risk can benefit from allogeneic hematopoietic stem cell transplantation, which will prolong their OS.
